Concepedia

Author

Caitlin D. Lowery

Eli Lilly (United States)

Also Known As

Caitlin D. Lowery, Caitlin Lowery

35

Publications

456

Citations

11

H-Index

15

Concepts

All Affiliations

Eli Lilly (United States)Prince of Songkla UniversityInstituto Nacional do CâncerLeningrad Regional Cancer CenterKanagawa Prefectural Hospital Organization
CD

About

Caitlin D. Lowery is an author at Eli Lilly (United States) specializing in tumor biology, cancer research, and surgical oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

30

2

Medicine

1

1

30

3

Immunology

1

1

30

4

Pathology

1

1

30

5

Surgical Oncology

1

1

30

Caitlin D. Lowery

×

9

Publications

369

Citations

9

H-Index

YearCitations

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Caitlin D. Lowery, Michele Dowless, Matthew Renschler,

Clinical Cancer Research

2018

79

The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma

Caitlin D. Lowery, Alle B. VanWye, Michele Dowless,

Clinical Cancer Research

2017

65

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

Michele Dowless, Caitlin D. Lowery, Terry J. Shackleford,

Clinical Cancer Research

2018

59

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

Solange Peters, Byoung Chul Cho, Alexander Luft,

Journal of Thoracic Oncology

2024

47

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α

Caitlin D. Lowery, Wayne Blosser, Michele Dowless,

Clinical Cancer Research

2017

34

MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma

Anthony P. Conley, Wei‐Lien Wang, J. Andrew Livingston,

Cancers

2019

30

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib

Wayne Blosser, Jack Dempsey, Ann M. McNulty,

Oncotarget

2020

25

Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy

Caitlin D. Lowery, Wayne Blosser, Michele Dowless,

Oncotarget

2019

17

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Edward B. Garon, Byoung Chul Cho, Alexander Luft,

Clinical Lung Cancer

2024

13

Page 1